Core Insights - Dexcom reported Q3 revenue of $1.21 billion, representing a 22% year-over-year increase, with net income rising to $283.8 million from $134.6 million in Q3 2024 [1][2] Financial Performance - Q3 revenue: $1.21 billion [1] - Year-over-year revenue increase: 22% [1] - Net income: $283.8 million, up from $134.6 million in Q3 2024 [1] Product Issues and Resolutions - Dexcom faced quality issues with its G7 continuous glucose monitors (CGMs) earlier in the year, specifically related to deployment failures [4] - The company has addressed these issues and expects a reduction in device complaints moving forward [3][4] - Improvements have been made to Bluetooth connectivity and adhesive quality of the CGMs [4] Customer Feedback and Market Impact - Executives reported stable complaint rates for the G7 devices, with ongoing efforts to enhance customer service [3][6] - There was a noted impact on new patient starts due to earlier product issues, but the company continues to see "hundreds of thousands" of new customer starts [6] - Feedback from prescribers indicates significant improvements in product performance after addressing initial challenges [5]